- Home
- BGLC vs CISS Comparison
BGLC vs CISS Comparison
Compare BGLC & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BGLC | CISS |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | Malaysia | Greece |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 1.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BGLC | CISS |
|---|---|---|
| Price | $2.28 | $2.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.1K | ★ 1.2M |
| Earning Date | 04-14-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,424,911.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.08 |
| 52 Week High | $15.19 | $6.06 |
Technical Indicators
Market Signals| Indicator | BGLC | CISS |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 45.61 |
| Support Level | $2.14 | $2.04 |
| Resistance Level | $2.73 | $2.81 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 69.15 | 4.10 |
Price Performance
Historical ComparisonAbout BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.